Meeting
2014 ASCO Annual Meeting
Salvage chemotherapy for relapsed germ cell tumors: A phase II trial of gemcitabine, paclitaxel, ifosfamide, and cisplatin (Gem-TIP).
Authors
Matthew James Wheater
University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
Matthew James Wheater , Robert Anthony Huddart , Jeff D. White , Gordon J. S. Rustin , Ivo M. Hennig , Kelly Cozens , Megan Bowers , Nadia Cross , Graham Mead
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Germ Cell/Testicular
Clinical Trial Registration Number
37453564
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 4560)
DOI
10.1200/jco.2014.32.15_suppl.4560
Abstract #
4560
Poster Bd #
128
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
GAMMA: Results from a phase II study for relapsed germ cell tumors using an oxaliplatin-based treatment regimen.
First Author: Kenrick Ng
Poster
2021 ASCO Annual Meeting
Efficacy of TIP (paclitaxel, ifosfamide and cisplatin) as salvage chemotherapy for relapsed germ cell cancer patients stratified by the modified International Prognostic Factors Study Group (IPFSG) score: The Northern Ireland (NI) Experience.
First Author: Adam Uprichard
Poster
2013 ASCO Annual Meeting
Gemcitabine, paclitaxel, and doxorubicin as first-line therapy for patients with advanced urothelial carcinoma and renal insufficiency: A phase II study.
First Author: Lance C. Pagliaro
Poster
2013 Genitourinary Cancers Symposium
Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).
First Author: Darren Richard Feldman